Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Accenture Sees AI Solutions For IDMP Compliance, Trial Efficiency

40% Of Client Sites Studied Recruited Zero Patients

Executive Summary

AI could help companies comply with regulations like GDPR and IDMP, apart from optimizing clinical trial processes, Accenture’s managing director leading R&D analytics in North America says, as he lists cases where the firm drove cost savings.

You may also be interested in...



Global R&D Heads Talk Superbugs, PROTACs And More

A panel of R&D experts from Merck’s EMD Serono, Boehringer Ingelheim, Takeda and Hilleman Labs discuss technologies like PROTACs and multi-specific antibodies, a superbug that could cause more damage than COVID-19 and the need for harmonized regulation that recognizes risk is essential to discovery

EU Decentralized Trials Guide Due Early In 2022

The upcoming EU guideline on decentralized clinical trials is the result of a “learning by doing” exercise and builds on various pilots and initiatives launched by different member states.

Parexel Exec Says Non-COVID-19 Drug Discovery Back With A Bang

Clinical trial initiations in cell and gene therapies and immuno-oncology are seeing a spike as the COVID-19 experience has shown the benefits of beginning research early, Parexel’s executive vice president says. In an interview with Scrip, Sanjay Vyas discusses a range of topics from diversity to the advantages of block chain and growth in China

Related Content

Topics

UsernamePublicRestriction

Register

SC146157

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel